Every Form 4 that Neuraxis, Inc. (NRXS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NRXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRXS filings page.
Neuraxis, INC (NRXS) reported insider equity compensation activity for officer Thomas Joeseph Carrico on 2026-08-24. Stock options for 306,236 shares were canceled and converted into an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, following approval by the board and stockholders. These RSUs vested immediately upon grant.
In a related event, 306,236 RSUs were granted and vested, and the company stated that, in connection with this vesting, 112,558 shares were withheld to satisfy income tax withholding and remittance obligations. After these events, 193,678 shares of common stock were acquired for the reporting person, bringing his directly held common stock position to 199,345 shares.
Neuraxis, Inc. (NRXS) reported that officer Adrian Miranda, CMO and SVP Science & Tech, had existing stock options canceled and replaced with restricted stock units under the company’s 2022 Omnibus Securities and Incentive Plan. 337,204 stock options were canceled in exchange for 337,204 RSUs, which vested immediately upon grant and converted into common stock. In connection with this vesting, 138,098 shares were withheld by Neuraxis to satisfy income tax obligations, and 199,106 common shares were issued and are now held directly by Miranda.
Neuraxis, INC (NRXS) reported equity compensation changes for Chief Executive Officer Brian Allen Carrico. On 2026-08-24, 320,000 stock options previously issued under a prior plan were canceled and converted into an equivalent 320,000 RSUs under the 2022 Omnibus Plan, with the RSUs vesting immediately upon grant. In connection with vesting, 120,812 shares of common stock were withheld to satisfy income tax obligations, and the remaining 199,188 shares were issued, bringing Carrico’s directly held common stock to 227,336 shares. These transactions were not reported as occurring under a Rule 10b5-1 trading plan.
Watkins Bradley Mitchell reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. (NRXS) reported that director Bradley Mitchell Watkins received an equity compensation grant of 26,073 shares of common stock on 2026-08-13. The shares were issued as compensation for services as an independent director, not as an open-market purchase, bringing his directly held stake to 72,408 shares.
Miranda Adrian reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. reported an equity compensation grant to executive Adrian Miranda, its CMO and SVP Science & Tech. Miranda received 133,341 RSUs, each representing one share of common stock, as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan. The RSUs vest in three equal annual installments over three years, and Miranda now directly holds 133,341 RSUs tied to common shares.
Keyser Jane Elizabeth reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. director Jane Elizabeth Keyser reported an award of 26,073 shares of Common Stock on 2026-08-13 at a reported value of $6.28 per share. The shares were issued as compensation for her services as an independent director. Following this grant, her direct holdings total 72,408 shares of Neuraxis common stock.
Henrichs Timothy Robert reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. (NRXS) reported an equity compensation grant to its Chief Financial Officer, Timothy Robert Henrichs. He received 141,479 RSUs, representing the right to receive an equal number of shares of common stock. The award was valued at $6.28 per unit for reporting purposes and was granted under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over three years, and the filing shows Henrichs holding 141,479 shares/units directly following this award.
Ferge Kristin A reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, INC director Kristin A. Ferge received a grant of 31,134 shares of common stock on 2026-08-13 at a reported value of $6.28 per share. The shares were issued as compensation for services as an independent director, bringing her directly held common stock position to 67,072 shares after the award.
Carrico Thomas Joeseph reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. reported that officer Thomas Joeseph Carrico received a grant of 135,906 RSUs of common stock as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan. The RSUs, valued at $6.28 per unit, vest in three equal annual installments over a three-year period, and Carrico now directly holds 135,906 RSUs.
Carrico Brian Allen reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. (NRXS) reported that Chief Executive Officer and director Brian Allen Carrico received a grant of 193,329 restricted stock units (RSUs) as equity compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. Following this award, his directly held RSU-based common stock position reported in this filing is 193,329 shares.
Neuraxis, INC director Aharon Gil reported three acquisitions of Common Stock of NRXS. On 2026-08-13, he received 43,930 shares at $6.28 per share as compensation for serving as an independent director. On 2026-07-29, he and Rosalind Master Fund L.P. received 2,226 and 40,068 shares, respectively, as stock dividends on their Series B Preferred Stock, based on accrued 8.5% cumulative dividends divided by $2.38. The 40,068-share position is reported as indirect ownership through Rosalind Advisors, Inc., with beneficial ownership disclaimed except for each party’s pecuniary interest, and total indirect holdings after these transactions are 548,123 shares.
Neuraxis (NRXS) director Aharon Gil reported stock awards tied to preferred share dividends rather than open‑market trading. On April 28, 2026, entities associated with him acquired 221,917 shares of common stock indirectly through Rosalind Master Fund L.P. and 12,304 shares directly.
These shares were issued as dividends on Series B Preferred Stock, calculated by dividing accrued and unpaid 8.5% cumulative dividends by $2.38 per share. Following the transactions, Gil’s reported holdings total 508,055 indirect shares and 33,902 direct shares of Neuraxis common stock.
Neuraxis, INC Chief Financial Officer buys company stock in open market trade. On April 1, 2026, CFO Timothy Robert Henrichs purchased 7,593 shares of Neuraxis common stock in an open-market transaction at a price of $1.96 per share. Following this purchase, he directly owns 7,593 shares.
Neuraxis, INC executive Thomas Joeseph Carrico, who serves as CRO, CCO and CPO, bought 667 shares of the company’s common stock in an open-market purchase at $1.96 per share. Following this transaction, he directly holds a total of 331,903 common shares.
Neuraxis, INC Chief Executive Officer Brian Allen Carrico purchased additional company stock in the open market. On April 1, 2026, he bought 8,060 shares of Neuraxis common stock at $1.96 per share.
After this transaction, Carrico directly owns 348,178 shares of Neuraxis common stock, modestly increasing his personal stake in the company.
Neuraxis, Inc. reported that executive Adrian Miranda, its CMO and SVP of Science & Technology, acquired 47,569 restricted stock units (RSUs) on January 22, 2026. These equity awards were granted as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan.
The RSUs vest in three equal annual installments over a three-year period, aligning Miranda’s compensation with longer-term company performance. After this grant, Miranda directly holds 47,569 derivative securities linked to Neuraxis common stock.
Watkins Bradley Mitchell reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. director Watkins Bradley Mitchell received a grant of 21,598 shares of common stock on January 22, 2026, as compensation for serving as an independent director. The shares were valued at $4.63 each, bringing his directly held stake to 46,335 shares after the award.
Neuraxis, INC director granted shares as equity compensation. Director Jane Elizabeth Keyser acquired 21,598 shares of Neuraxis common stock on January 22, 2026 at a stated price of $4.63 per share through a grant, not an open-market purchase.
After this award, she directly owns 46,335 common shares. According to the disclosure, these shares were issued as compensation for her services as an independent director, meaning this is a non-cash equity grant rather than a cash investment into the company’s stock.
Neuraxis, Inc. reported that its Chief Financial Officer, Timothy Robert Henrichs, acquired 75,231 restricted stock units (RSUs) on common stock as an equity award. The RSUs were granted at a reference value of $4.63 per share and will vest in three equal annual installments over a three-year period, aligning the CFO’s compensation with long-term shareholder interests. All 75,231 RSUs are held as direct ownership following this grant.
Carrico Brian Allen reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. Chief Executive Officer Brian Allen Carrico reported an award of 94,173 restricted stock units (RSUs) on common stock. The RSUs were granted as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended.
The RSUs vest in three equal annual installments over a three-year period, meaning portions of the award will be delivered over time if service-based conditions are met. This is an equity-based compensation grant, not an open-market share purchase or sale.
Neuraxis, Inc. 10% owner Brian P. Hannasch reported open-market purchases of the company’s common stock. He bought 40,000 shares on February 11, 2026 at a weighted average price of $4.65 per share and another 40,000 shares on February 12, 2026 at a weighted average price of $4.92 per share. Following these transactions, he directly beneficially owned 1,211,522 shares of Neuraxis common stock.
Neuraxis, Inc. director receives stock compensation. On 01/22/2026, the director was awarded 21,598 common shares at $4.63 per share as compensation for serving as an independent director. After this grant, the director beneficially owns 307,736 shares, including 286,138 shares held by Rosalind Master Fund L.P.
Neuraxis, Inc. director Kristin A. Ferge received 21,598 shares of common stock on January 22, 2026, reported as an "A" (acquired) transaction. The shares were issued at $4.63 per share as compensation for her services as an independent director. Following this grant, she directly owns 35,938 shares of Neuraxis common stock.
Neuraxis Inc. director Gil Aharon reported an indirect purchase of company stock. On 12/23/2025, an affiliate, Rosalind Master Fund L.P., purchased 286,138 common shares of Neuraxis at $3.52 per share, as disclosed in a Form 4 filing. The shares are held indirectly through Rosalind Advisors, Inc., which serves as advisor to Rosalind Master Fund L.P.
The filing notes that each reporting person disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest, meaning the economic exposure is limited to their financial stake in the fund rather than full ownership of all reported shares.